ALSAF SAFE

SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS

SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS

SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS

A major partnership to accelerate Safe's development in the Spanish market

Fleurieux-sur-l’Arbresle – France – December 17, 2025 8am - Safe (FR001400ZU25 – ALSAF) announces the signing of an exclusive distribution agreement with , a subsidiary of Vortrom, for the Spanish market.

A strategic partnership with a leading player

For more than 40 years, Vortrom, a major distributor of medical equipment in Spain, is now appointed exclusive partner of the Safe Group for the distribution of its surgical solutions throughout Spain. This strategic alliance is part of Safe's commitment to accelerating its international expansion and strengthening its presence in key European markets by offering increasingly innovative solutions that meet the highest standards, improve surgical techniques, facilitate patient recovery, and reduce the cost of procedures.

Thanks to its extensive distribution network, recognized expertise in the orthopedic sector, and in-depth knowledge of the Spanish market, Vortrom Biologics has the assets to ensure the optimal deployment of Safe solutions in healthcare facilities and among spinal surgery professionals.

A significant growth opportunity

Spain is a strategic market for Safe, with over 47 million inhabitants and a modern healthcare system offering significant growth potential. This partnership will enable Safe to leverage Vortrom's commercial strength and credibility to effectively penetrate this market.

Philippe Laurito, CEO of Safe Group, said: “We are very proud to be partnering with Vortrom, a major and respected player in the Spanish market. This agreement demonstrates the appeal of our innovative solutions and our ability to forge strategic partnerships with leading distributors. Vortrom's expertise and established network will enable us to significantly accelerate our development in Spain.

Lucía Muñoz, CEO of Vortrom Biologics, said: “We are delighted to add Safe's innovative solutions to our portfolio. These technologies perfectly meet the needs of Spanish surgeons and are in line with our strategy of offering our customers the most advanced solutions on the market.”

About Safe Group

Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 people.

Safe Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United States.

For more information:

Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile packaging.

For more information:

Contact

SAFE GROUP                                                AELYON ADVISORS

                        

Attachment



EN
17/12/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SAFE

 PRESS RELEASE

SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BI...

SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS A major partnership to accelerate Safe's development in the Spanish market Fleurieux-sur-l’Arbresle – France – December 17, 2025 – 8am - Safe (FR001400ZU25 – ALSAF) announces the signing of an exclusive distribution agreement with , a subsidiary of Vortrom, for the Spanish market. A strategic partnership with a leading player For more than 40 years, Vortrom, a major distributor of medical equipment in Spain, is now appointed exclusiv...

 PRESS RELEASE

SAFE ANNONCE LA SIGNATURE D'UN CONTRAT DE DISTRIBUTION STRATEGIQUE EN ...

SAFE ANNONCE LA SIGNATURE D'UN CONTRAT DE DISTRIBUTION STRATEGIQUE EN ESPAGNE AVEC VORTROM BIOLOGICS SAFE ANNONCE LA SIGNATURE D'UN CONTRAT DE DISTRIBUTION STRATEGIQUE EN ESPAGNE AVEC VORTROM BIOLOGICS Un partenariat majeur pour accélérer le développement de Safe sur le marché espagnol Fleurieux-sur-l’Arbresle – France – 17 décembre 2025 – 8h - Safe (FR001400ZU25 – ALSAF) annonce la signature d'un accord de distribution exclusif avec Biologics – filiale de Vortrom - pour le marché espagnol. Un partenariat stratégique avec un acteur de référence Depuis plus de 40 ans, Vortrom, distribut...

 PRESS RELEASE

SAFE - RESULTATS SEMESTRIELS 2025

SAFE - RESULTATS SEMESTRIELS 2025 RESULTATS SEMESTRIELS 2025 Fleurieux-sur-l’Arbresle – France – 9 décembre 2025 – 18h - Safe (FR001400ZU25 – ALSAF) annonce ses résultats semestriels et avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés Financiers son rapport financier semestriel au 30 juin 2025. Compte de résultat consolidé – en milliers d’euros31/12/202430/06/2025Chiffre d’affaires5 0412 526Achats consommés(2 391)(757)Charges externes(4 868)(1 785)Charges de personnel(3 020)(1 540)Impôts et taxes (59)(30)Dotations nettes aux amortissements, dépréciations et ...

 PRESS RELEASE

SAFE - Mise à disposition du Rapport Financier Semestriel 2025

SAFE - Mise à disposition du Rapport Financier Semestriel 2025 Mise à disposition du Rapport Financier Semestriel 2025 Fleurieux-sur-l’Arbresle - France - le 8 décembre 2025 à 14h. Safe SA (FR001400F1V2 – ALSAF), spécialiste dans la conception, la fabrication et la commercialisation de dispositifs médicaux dédiés à la chirurgie du rachis, annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés Financiers son rapport financier semestriel au 30 juin 2025. Le rapport financier semestriel 2025 peut être consulté sur le site de SAFE, , dans la rubrique . À prop...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch